Diabetic Retinopathy - Pipeline Review, H2 2017

  • ID: 4426912
  • Report
  • 195 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abzena Plc
  • BCN Peptides SA
  • EyeGene Inc
  • Kowa Co Ltd
  • Nemus Bioscience Inc
  • Promedior Inc
  • MORE
Diabetic Retinopathy - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 6, 1, 38, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abzena Plc
  • BCN Peptides SA
  • EyeGene Inc
  • Kowa Co Ltd
  • Nemus Bioscience Inc
  • Promedior Inc
  • MORE
Introduction

Diabetic Retinopathy - Overview

Diabetic Retinopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Retinopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Retinopathy - Companies Involved in Therapeutics Development

Abzena Plc

Acucela Inc

Aerie Pharmaceuticals Inc

Aerpio Therapeutics Inc

Antisense Therapeutics Ltd

AntriaBio Inc

BCN Peptides SA

Boehringer Ingelheim GmbH

Charlesson LLC

Coherus BioSciences Inc

Crinetics Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics Inc

EyeGene Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Icon Bioscience Inc

Islet Sciences Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

M's Science Corp

Mabion SA

Navigen Inc

Nemus Bioscience Inc

Oculis ehf

Ohr Pharmaceutical Inc

PanOptica Inc

Profarma

Promedior Inc

Regeneron Pharmaceuticals Inc

Ribomic Inc

Strongbridge Biopharma plc

Sylentis SAU

ThromboGenics NV

VESSL Therapeutics Ltd

Diabetic Retinopathy - Drug Profiles

(irbesartan + propagermanium) - Drug Profile

A-717 - Drug Profile

AB-402 - Drug Profile

AC-301 - Drug Profile

aflibercept - Drug Profile

aflibercept biosimilar - Drug Profile

AKB-9778 - Drug Profile

Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile

APTA-1004 - Drug Profile

Aptamers for Diabetic Retinopathy - Drug Profile

AQA-001 - Drug Profile

AR-13154 - Drug Profile

atesidorsen sodium - Drug Profile

BI-1467335 - Drug Profile

BI-690517 - Drug Profile

Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile

BNN-27 - Drug Profile

Cell Therapy for Diabetic Retinopathy - Drug Profile

CLT-005 - Drug Profile

CLT-020 - Drug Profile

CRN-00808 - Drug Profile

cyclosporine - Drug Profile

Cyndacel-M - Drug Profile

DRGT-109 - Drug Profile

DT-23552 - Drug Profile

DYN-12 - Drug Profile

E-1086 - Drug Profile

EG-Mirotin - Drug Profile

emixustat hydrochloride - Drug Profile

fenofibrate - Drug Profile

FP-008 - Drug Profile

Gene Therapy for Diabetic Retinopathy - Drug Profile

GLY-230 - Drug Profile

HCB-1019 - Drug Profile

IVMED-60 - Drug Profile

JP-153 - Drug Profile

KSI-301 - Drug Profile

magacizumab - Drug Profile

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile

MS-553 - Drug Profile

NB-2222 - Drug Profile

NM-108 - Drug Profile

OC-410 - Drug Profile

ocriplasmin - Drug Profile

OCU-200 - Drug Profile

OCX-063 - Drug Profile

PAN-90806 - Drug Profile

Peptagon - Drug Profile

PF-07 - Drug Profile

PRM-167 - Drug Profile

Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

RBM-008 - Drug Profile

Recombinant Protein for Oncology, Diabetic Retinopathy and Retinopathy Of Prematurity - Drug Profile

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile

Recombinant Proteins to Inhibit VEGFA for Diabetic Retinopathy - Drug Profile

Resolvine ER - Drug Profile

ripasudil - Drug Profile

RO-5461111 - Drug Profile

RT-001 - Drug Profile

RT-002 - Drug Profile

SBT-200 - Drug Profile

Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile

somatostatin - Drug Profile

squalamine lactate - Drug Profile

Stem Cell Therapy for Diabetic Retinopathy - Drug Profile

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile

SYL-136001v10 - Drug Profile

THR-687 - Drug Profile

Vaxier-001 - Drug Profile

veldoreotide - Drug Profile

Wnt-001 - Drug Profile

Diabetic Retinopathy - Dormant Projects

Diabetic Retinopathy - Discontinued Products

Diabetic Retinopathy - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Diabetic Retinopathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diabetic Retinopathy - Pipeline by Abzena Plc, H2 2017

Diabetic Retinopathy - Pipeline by Acucela Inc, H2 2017

Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H2 2017

Diabetic Retinopathy - Pipeline by Aerpio Therapeutics Inc, H2 2017

Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H2 2017

Diabetic Retinopathy - Pipeline by AntriaBio Inc, H2 2017

Diabetic Retinopathy - Pipeline by BCN Peptides SA, H2 2017

Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Diabetic Retinopathy - Pipeline by Charlesson LLC, H2 2017

Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H2 2017

Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017

Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H2 2017

Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2017

Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Diabetic Retinopathy - Pipeline by Icon Bioscience Inc, H2 2017

Diabetic Retinopathy - Pipeline by Islet Sciences Inc, H2 2017

Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H2 2017

Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H2 2017

Diabetic Retinopathy - Pipeline by Lupin Ltd, H2 2017

Diabetic Retinopathy - Pipeline by M's Science Corp, H2 2017

Diabetic Retinopathy - Pipeline by Mabion SA, H2 2017

Diabetic Retinopathy - Pipeline by Navigen Inc, H2 2017

Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H2 2017

Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2017

Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H2 2017

Diabetic Retinopathy - Pipeline by PanOptica Inc, H2 2017

Diabetic Retinopathy - Pipeline by Profarma, H2 2017

Diabetic Retinopathy - Pipeline by Promedior Inc, H2 2017

Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Diabetic Retinopathy - Pipeline by Ribomic Inc, H2 2017

Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H2 2017

Diabetic Retinopathy - Pipeline by Sylentis SAU, H2 2017

Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2017

Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2017

Diabetic Retinopathy - Dormant Projects, H2 2017

Diabetic Retinopathy - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Diabetic Retinopathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abzena Plc
  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Therapeutics Inc
  • Antisense Therapeutics Ltd
  • AntriaBio Inc
  • BCN Peptides SA
  • Boehringer Ingelheim GmbH
  • Charlesson LLC
  • Coherus BioSciences Inc
  • Crinetics Pharmaceuticals Inc
  • Dimerix Bioscience Pty Ltd
  • Dynamis Therapeutics Inc
  • EyeGene Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals LLC
  • Icon Bioscience Inc
  • Islet Sciences Inc
  • Kodiak Sciences Inc
  • Kowa Co Ltd
  • Lupin Ltd
  • M's Science Corp
  • Mabion SA
  • Navigen Inc
  • Nemus Bioscience Inc
  • Oculis ehf
  • Ohr Pharmaceutical Inc
  • PanOptica Inc
  • Profarma
  • Promedior Inc
  • Regeneron Pharmaceuticals Inc
  • Ribomic Inc
  • Strongbridge Biopharma plc
  • Sylentis SAU
  • ThromboGenics NV
  • VESSL Therapeutics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll